| Sherif George El Bayadi, MD | |
|
945 E Genesee St, Suite 200, Syracuse, NY 13210-1752 | |
| (315) 475-8401 | |
| Not Available |
| Full Name | Sherif George El Bayadi |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 42 Years |
| Location | 945 E Genesee St, Syracuse, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730127168 | NPI | - | NPPES |
| 01152318 | Medicaid | NY | |
| 290010706 | Other | NY | RR MEDICARE |
| 00485070 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 171169 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph's Hospital Health Center | Syracuse, NY | Hospital |
| Oswego Hospital | Oswego, NY | Hospital |
| Entity Name | St Josephs Hospital Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508815333 PECOS PAC ID: 9234043324 Enrollment ID: O20031113000400 |
News Archive
Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike.
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
Students from four of Arizona State University's graduate programs traveled to a country known as the Land of 1,000 Hills to study health care and building design in one of Africa's most impoverished areas.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
› Verified 4 days ago
| Entity Name | New York Anesthesiology Medical Specialties Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841285996 PECOS PAC ID: 3375535396 Enrollment ID: O20040331000822 |
News Archive
Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike.
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
Students from four of Arizona State University's graduate programs traveled to a country known as the Land of 1,000 Hills to study health care and building design in one of Africa's most impoverished areas.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
› Verified 4 days ago
| Entity Name | Pulmonary Health Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063450484 PECOS PAC ID: 3375430630 Enrollment ID: O20060811000449 |
News Archive
Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike.
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
Students from four of Arizona State University's graduate programs traveled to a country known as the Land of 1,000 Hills to study health care and building design in one of Africa's most impoverished areas.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
› Verified 4 days ago
| Entity Name | Oneida Medical Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932398997 PECOS PAC ID: 9830272350 Enrollment ID: O20080207000050 |
News Archive
Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike.
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
Students from four of Arizona State University's graduate programs traveled to a country known as the Land of 1,000 Hills to study health care and building design in one of Africa's most impoverished areas.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
› Verified 4 days ago
| Entity Name | St Josephs Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942501747 PECOS PAC ID: 4688855844 Enrollment ID: O20110221000744 |
News Archive
Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike.
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
Students from four of Arizona State University's graduate programs traveled to a country known as the Land of 1,000 Hills to study health care and building design in one of Africa's most impoverished areas.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sherif George El Bayadi, MD 945 E Genesee St, Suite 200, Syracuse, NY 13210-1752 Ph: (315) 475-8401 | Sherif George El Bayadi, MD 945 E Genesee St, Suite 200, Syracuse, NY 13210-1752 Ph: (315) 475-8401 |
News Archive
Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike.
Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.
Students from four of Arizona State University's graduate programs traveled to a country known as the Land of 1,000 Hills to study health care and building design in one of Africa's most impoverished areas.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
› Verified 4 days ago
Courtney Myers, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 750 E Adams St Ste 311, Syracuse, NY 13210 Phone: 315-464-5815 | |
Joan Marie Mitchell, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-425-4828 Fax: 315-425-4827 | |
Gordana Obradovic, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1304 Buckley Rd, Suite 200, Syracuse, NY 13212 Phone: 315-478-3311 Fax: 315-476-5211 | |
Kristin A Ramella, NP Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Presidential Plz Ste 5010, Syracuse, NY 13202 Phone: 315-464-9335 | |
Vinodhini M Subramanian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-470-7111 | |
Robert R. Michiel, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 90 Presidential Plz, 5th Floor, Syracuse, NY 13202 Phone: 315-464-9335 Fax: 315-464-9338 | |
Michael P Gabris, MD FACC Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 E Genesee St, Suite 300, Syracuse, NY 13210 Phone: 315-471-1044 Fax: 315-474-4312 |